Skip to main content

Table 1 Patient demographics and baseline characteristics by age group (ITTI population)

From: Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan

Variable

< 6 years

N = 56

≥6 to < 12 years

N = 81

Overall

N = 137

Age (years)

2.9 ± 1.7

8.5 ± 1.6

6.2 ± 3.2

 Median

3.0

9.0

7.0

 Range

0–5

6–11

0–11

Male, n (%)

21 (37.5)

43 (53.1)

64 (46.7)

Weight (kg)

13.53 ± 3.80

28.34 ± 7.87

22.29 ± 9.78

 Median

14.40

26.60

20.90

 Range

4.0–21.3

16.5–51.0

4.0–51.0

Body temperature (°C)

38.84 ± 0.52

38.82 ± 0.63

38.83 ± 0.58

 Median

38.80

38.70

38.80

 Range

38.0–40.2

38.0–40.5

38.0–40.5

Sum of two symptom scoresa

2.6 ± 1.3

3.3 ± 1.0

3.0 ± 1.2

 Median

3.0

3.0

3.0

 Range

0–5

0–6

0–6

Time to treatment from influenza onset, n (%)

  ≥ 0 to ≤12 hours

23 (41.1)

35 (43.2)

58 (42.3)

  > 12 to ≤24 hours

26 (46.4)

33 (40.7)

59 (43.1)

  > 24 to ≤36 hours

6 (10.7)

11 (13.6)

17 (12.4)

  > 36 to ≤48 hours

1 (1.8)

2 (2.5)

3 (2.2)

Influenza virus type (subtype) based on RT-PCR, n (%)

 A(H1N1)pdm09

9 (16.1)

4 (4.9)

13 (9.5)

 A(H3N2)

27 (48.2)

69 (85.2)

96 (70.1)

 B

16 (28.6)

4 (4.9)

20 (14.6)

 A, subtype not specified

2 (3.6)

2 (2.5)

4 (2.9)

 Mixed infection

2 (3.6)

2 (2.5)

4 (2.9)

Influenza vaccinationb, n (%)

15 (26.8)

21 (25.9)

36 (26.3)

Co-infection with respiratory virus or bacteriac, n (%)

25 (44.6)

25 (30.9)

50 (36.5)

  1. Data are presented as mean ± SD unless otherwise stated
  2. ITTI intention-to-treat infected, RT-PCR reverse transcription polymerase chain reaction, SD standard deviation
  3. aCough symptom score and nasal discharge/nasal congestion symptom score
  4. bVaccinated within the last 6 months
  5. cPatients positive for influenza virus and positive for viruses or bacteria other than influenza at ≥1 time point. The following viruses were detected: adenovirus, bocavirus, coronavirus HKU1, coronavirus OC43, coronavirus NL63, enterovirus, human metapneumovirus, parainfluenza 1, parainfluenza 2, parainfluenza 4, rhinovirus, RSV-A and RSV-B (details in Additional file 2: Table S1)